ATAI Life Sciences BV (ATAI) Peer Comparison
$7.35
$0.00 (0.00%)As on 11-Sep-2026 09:30EDT
Market cap
$2,726 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
15.5
Div. Yield
0 %
Edit
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,726 | 8,681 | 2,190 | 1,627 | 231 |
Revenue ($ Mln) |
4 | 2,100 | -- | 19 | 19 |
Net Profit ($ Mln) |
-668.19 | 409.32 | -171.57 | -252.21 | -42.32 |
Net Margin (%) |
-14,938.37 | 19.49 | -- | -1,350.73 | -228.38 |
RoE (%) |
-335.53 | 11.47 | -59.98 | -96.46 | -65.71 |
Price to Earnings |
-- | 22.24 | -- | -- | -- |
Price-To-Book |
15.46 | 2.69 | 6.74 | 9.15 | 2.63 |
Cashflow ($ Mln)
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-102.68 | 654.33 | -137.07 | -177.96 | -52.79 |
|
Cash Flow from Investing Activities
|
-109.13 | -305.28 | -0.16 | -321.62 | -1.02 |
|
Cash from Financing Activities
|
269.48 | -178.98 | 160.61 | 415.40 | -1.84 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-361.72 | 8.01 | -64.99 | -50.07 | -44.48 |
|
ROE (%)
|
-335.53 | 11.47 | -59.98 | -96.46 | -65.71 |
|
ROA (%)
|
-263.03 | 6.10 | -58.07 | -29.77 | -22.01 |
|
EBIT Margin (%)
|
-15,198.77 | 23.80 | -- | -1,047.15 | -229.99 |
|
Net Margin (%)
|
-14,938.37 | 19.49 | -- | -1,350.73 | -228.38 |
|
Cash Profit Margin (%)
|
-0.02 | 0.00 | -- | 0.00 | 0.00 |
Growth Ratios
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
93.72 | 2.96 | -- | 30.24 | 12.40 |
|
EBIT Growth (%)
|
-530.01 | -4.99 | -35.87 | -44.77 | -13.38 |
|
Net Profit Growth (%)
|
-459.61 | 9.62 | -1.94 | -26.74 | -6.67 |
|
EPS Growth (%)
|
-316.60 | 14.23 | 15.07 | -4.52 | 6.83 |
|
Book Value Growth (%)
|
-33.14 | 0.56 | 31.10 | 6,797.66 | -3.20 |
Valuation Ratios
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.38 | 21.99 | -10.30 | -6.92 | -5.14 |
|
Price / Book Value
|
4.09 | 2.47 | 6.67 | 6.92 | 3.59 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.99 | 13.80 | -8.76 | -11.07 | -3.13 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.48 | 0.00 | 0.15 | 0.00 |
|
Short term debt to equity ratio
|
0.02 | 0.00 | 0.00 | 0.01 | 0.06 |
|
Current Ratio
|
8.58 | 2.85 | 11.94 | 10.01 | 3.49 |
|
Quick Ratio
|
8.58 | 2.31 | 11.94 | 10.01 | 3.49 |
|
Interest Coverage
|
-334,090.00 | 12.71 | -1,045.90 | -3.11 | -45.75 |
Operating Efficiency Ratios
| ATAI Life Sciences BV (ATAI) | Qiagen N.V. - ADR | Pharvaris BV (PHVS) | Uniqure NV (QURE) | ProQR Therapeutics N.V. - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
14.46 | 19.00 | -- | 30.94 | 10.03 |
|
Asset Turnover
|
0.02 | 0.31 | 0.00 | 0.02 | 0.10 |
|
Receivable days
|
704.55 | 75.29 | -- | 133.23 | 96.49 |
|
Inventory Days
|
-- | 132.91 | -- | 0.00 | -- |
|
Payable days
|
1,357.42 | 35.66 | -- | 1,342.82 | 25.78 |
|
Cash Conversion Cycle
|
-- | 172.54 | -- | -1,209.59 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
